Based on the Aurinia Pharmaceuticals Inc stock forecast from 1 analysts, the average analyst target price for Aurinia Pharmaceuticals Inc is USD 11.00 over the next 12 months. Aurinia Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aurinia Pharmaceuticals Inc is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, Aurinia Pharmaceuticals Inc’s stock price was USD 8.18. Aurinia Pharmaceuticals Inc’s stock price has changed by +5.55% over the past week, -3.31% over the past month and +66.60% over the last year.
No recent analyst target price found for Aurinia Pharmaceuticals Inc
No recent average analyst rating found for Aurinia Pharmaceuticals Inc
Company Overview Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. Read Less
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephri...Read More
Frequently Asked Questions About Aurinia Pharmaceuticals Inc (AUPH) Stock
Based on ratings from 1 analysts Aurinia Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on AUPH's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AUPH is USD 11.00 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 11.
AUPH stock's Price/Earning ratio is 204.50.
Our analysis grades AUPH stock's Price / Earning ratio at F. This means that AUPH stock's Price/Earning ratio is above 95% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AUPH may be a overvalued for its sector.
The last closing price of AUPH's stock was USD 8.18.
The most recent market capitalization for AUPH is USD 1.12B.
Based on targets from 1 analysts, the average taret price for AUPH is projected at USD 11.00 over the next 12 months.
This means that AUPH's stock price may go up by +34.47% over the next 12 months.
We can't find any ETFs which contains Aurinia Pharmaceuticals Inc's stock.
As per our most recent records Aurinia Pharmaceuticals Inc has 130 Employees.
Aurinia Pharmaceuticals Inc's registered address is #140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6.
You can get more information about it from Aurinia Pharmaceuticals Inc's website at https://www.auriniapharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Aurinia Pharmaceuticals Inc (AUPH) Stock
Based on ratings from 1 analysts Aurinia Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on AUPH's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AUPH is USD 11.00 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 11.
AUPH stock's Price/Earning ratio is 204.50.
Our analysis grades AUPH stock's Price / Earning ratio at F. This means that AUPH stock's Price/Earning ratio is above 95% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AUPH may be a overvalued for its sector.
The last closing price of AUPH's stock was USD 8.18.
The most recent market capitalization for AUPH is USD 1.12B.
Based on targets from 1 analysts, the average taret price for AUPH is projected at USD 11.00 over the next 12 months.
This means that AUPH's stock price may go up by +34.47% over the next 12 months.
We can't find any ETFs which contains Aurinia Pharmaceuticals Inc's stock.
As per our most recent records Aurinia Pharmaceuticals Inc has 130 Employees.
Aurinia Pharmaceuticals Inc's registered address is #140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6.
You can get more information about it from Aurinia Pharmaceuticals Inc's website at https://www.auriniapharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AUPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
